Project Grant F31CA314085
Award Date 12/15/26
Completion Date 7/15/28
Dollars Obligated $100K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06510, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Yale University $149,190 on December 27, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support training and research in basic, clinical, and prevention research important to the National Cancer Program. The funded work investigates the anti-tumor roles of tumor-draining lymph nodes in renal cell carcinoma, examining how CD8+ T cells—critical mediators of anti-tumor immunity—differentiate and sustain immune...
- The National Cancer Institute awarded Yale University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and biomedical career development in cancer research. Yale will conduct basic research on the regulation of membrane-chromatin interactions during mitotic nuclear formation and their role in cancer cell survival. The project investigates how endoplasmic reticulum membranes and LEM-domain proteins, including LEMD2 and emerin,...
- The National Cancer Institute awarded Yale University $104,902 under the Cancer Research Manpower program (CFDA 93.398) on September 30, 2026, to support research investigating the immunobiology of tumor-specific T follicular helper CD4 T cells and their role in response to immune checkpoint blockade cancer therapies. The research employs spatiotemporal tracking, cyclic immunofluorescence, flow cytometry, and single-cell RNA sequencing to define factors that generate interleukin-21...
- Federal Grant Award Summary The National Cancer Institute awarded Yale University a $478,532 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This research initiative will investigate the biological and clinical significance of spatial immune heterogeneity in non-small cell lung cancer (NSCLC), with particular focus on characterizing how the spatial distribution of tumor-infiltrating lymphocytes (TILs) and tertiary...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Yale University $696,189 on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms of CD8 T cell differentiation in tumor-draining lymph nodes. The research examines how CD8 T cells—specifically progenitor-exhausted (TPEX) cells housed in tumor-draining lymph nodes associated with lung adenocarcinoma—maintain stemlike properties and...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of California Irvine $648,626 on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy. The funded research examines why PD-1 checkpoint inhibitors fail in most cancer patients despite providing durable benefits in approximately 40 percent of patients with metastatic melanoma and...
- The National Cancer Institute awarded Yale University $577,750 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the chromatin remodeling complex PBAF in small cell lung cancer. The research aims to elucidate the chromatin, epigenetic, and transcriptional mechanisms that promote small cell lung cancer development and to translate mechanistic findings toward clinical therapeutics. Yale's investigation focuses on recurrent inactivating mutations...
- The National Institutes of Health National Cancer Institute awarded Yale University $684,252 on June 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the functions and mechanisms of innate lymphoid cells type 2 (ILC2s) in trained immunity. The research examines how ILC2s in bone marrow establish and sustain trained immunity—an epigenetic memory process in hematopoietic stem and progenitor cells that produces robust immune responses to subsequent inflammatory...
- The National Cancer Institute awarded Yale University $610,637 in project grant funding on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer and optimize drug delivery platforms for locoregional treatment of advanced melanoma. Yale will develop bioadhesive and non-adhesive biodegradable nanoparticles engineered to deliver cytotoxic and immune conditioning agents selectively to tumor cells, the tumor microenvironment, and tumor-draining lymph nodes. The research...
- The National Cancer Institute awarded The Leland Stanford Junior University $143,278 under the Cancer Research Manpower program (CFDA 93.398) on January 1, 2026, to support research investigating evolutionary antagonism between tumors and lymphocytes. The recipient will conduct analyses of clonal diversity in metastatic cancer cells using viral integration site mapping across nine rounds of in vivo selection, perform single-cell transcriptomics to profile phenotypic diversity in relation to...